U.S. Health Officials Start First Clinical Trial With Gilead Sciences' Experimental Coronavirus Treatment [The Motley Fool]
![The Motley Fool](../../../Content/images/providers/The Motley Fool.png)
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: The Motley Fool
On Tuesday, officials from the National Institute of Health (NIH) announced the initiation of a clinical trial in which patients in U.S. hospitals with confirmed COVID-9 infections will be given Gilead Sciences' NASDAQ:GILD What we know The first clinical trial participant was an American currently at the Nebraska Medical Center in Omaha, who had been quarantined with other infected passengers from the Diamond Princess cruise ship. Image source: Getty Images. While we can be fairly certain the first trial participant won't be in a hurry to take another cruise, that's really all we know about this person at the moment. The NIH and Gilead Sciences will most likely randomize patients into groups receiving remdesivir or a placebo, so don't discount remdesivir's potential as a COVID-9 treatment if you don't see news of about the rapid recovery from that first enrolled U.S. patient in the next couple of days. Health officials at the China-Japan Friendship Hospital and other centers in Hubei
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Moderna (MRNA) Q4 Earnings Report Preview: What To Look For [Yahoo! Finance]Yahoo! Finance
- IDEAYA announces expanded collaboration with Gilead Sciences [Seeking Alpha]Seeking Alpha
- Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at DZ Bank AG from a "hold" rating to a "buy" rating. They now have a $108.00 price target on the stock.MarketBeat
- February 2025's Undervalued Stock Selections For Potential Investment Opportunities [Yahoo! Finance]Yahoo! Finance
- Why Gilead Sciences (GILD) Stock Is Trading Up Today [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 2/11/25 - Beat
GILD
Sec Filings
- 2/13/25 - Form 4
- 2/13/25 - Form 13F-HR
- 2/12/25 - Form 144
- GILD's page on the SEC website